Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
05/19/2017 05/22/2017 05/23/2017 05/24/2017 05/25/2017 Date
5119(c) 5130(c) 5141(c) 5185(c) 5209 Last
2 921 092 2 188 205 1 930 849 2 321 168 1 788 098 Volume
-0.41% +0.21% +0.21% +0.86% +0.46% Change
More quotes
Financials ($)
Sales 2017 21 431 M
EBIT 2017 5 796 M
Net income 2017 2 671 M
Debt 2017 12 464 M
Yield 2017 4,06%
Sales 2018 22 247 M
EBIT 2018 6 138 M
Net income 2018 3 280 M
Debt 2018 13 485 M
Yield 2018 4,11%
P/E ratio 2017 31,15
P/E ratio 2018 24,81
EV / Sales2017 4,55x
EV / Sales2018 4,43x
Capitalization 85 042 M
More Financials
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products.The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.Its... 
More about the company
Surperformance© ratings of AstraZeneca plc
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTRAZENECA PLC
04:01p ASTRAZENECA : Brilique (ticagrelor) new formulation gains European approval
12:24p ASTRAZENECA : enters agreement with Recordati for Seloken in Europe
10:46a ASTRAZENECA : Francis Crick Institute signs new research agreement with AstraZen..
05/24 FTSE edges up helped by M&S, but miners weigh
05/24 ASTRAZENECA : enters agreement with Recordati for Seloken in Europe
05/24 ASTRAZENECA : signs deal to sell commercial rights for Seloken in Europe
05/24 ROCHE : receives FDA approval for complementary PD-L1 (SP263) biomarker test
05/24 ASTRAZENECA : and the Francis Crick Institute sign research agreement
05/24 ASTRAZENECA : cheers a success for PhIII benralizumab study; TP raises $45M for ..
05/23 ASTRAZENECA : trial indicates diabetes drug had no big cardiac side-effects
More news
Sector news : Pharmaceuticals - NEC
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ASTRAZENECA PLC 
2016A rally could take place
More Strategies
Latest Tweets
03:03aAstraZeneca plc $AZN Position Lowered by Bristol Advisors LLC  
03:03a7,000 Shares in AstraZeneca plc $AZN Acquired by Doheny Asset Management CA  
05/24$ALBO: Albireo Pharma prices $45.1 mln common stock offering at a price to th.. 
05/24Albireo Pharma downgraded by Zacks Investment Research to sell.  
05/24AstraZeneca's new benralizumab helps severe asthma patients cut back on stero..
More tweets
News from SeekingAlpha
05/24 Healthcare Unicorns And Where To Find Them
05/23 Study shows AstraZeneca's T2D med Bydureon does not increase CV risk
05/23 Don't Give Up On Splunk - Cramer's Lightning Round (5/22/17)
05/23 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2017 Update
05/22 AstraZeneca's benralizumab shows significant treatment effect in severe asthm..
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 65,9 $
Spread / Average Target -2,0%
Consensus details
EPS Revisions
More Estimates Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.68%342 817
ROCHE HOLDING LTD.15.18%237 610
NOVARTIS AG6.68%213 719
PFIZER INC.-1.32%191 279
MERCK & CO., INC.10.29%175 160
More Results